Ex-PRESS better than trabeculectomy

Article

The Ex-PRESS implant appears to be as effective as trabeculectomy, furthermore it reduces postoperative compliance issues and seems to be safer, according to a paper presented at this year's World Glaucoma Congress held in Singapore.

The Ex-PRESS implant appears to be as effective as trabeculectomy, furthermore it reduces postoperative compliance issues and seems to be safer, according to a paper presented at this year's World Glaucoma Congress held in Singapore.

In a prospective clinical study, 34 pseudophakic glaucomatous subjects, not controlled by topical therapy, were randomized into two groups to receive either the Ex-PRESS implant or undergo trabeculectomy. All subjects had a postoperative intraocular pressure (IOP) measurement over 24 mmHg.

In the Ex-PRESS group (17 subjects), preoperative IOP was 26±2.18 mmHg and in the trabeculectomy group (17 subjects) it was 26.7±1.98 mmHg. At one week follow-up the mean IOP had fallen to 14±4.2 mmHg (p=<0.001) and 15.4±3.6 mmHg (P=<0.001), in the Ex-PRESS and trabeculectomy group, respectively. In the Ex-PRESS group, two eyes required an anterior chamber (AC) viscoelastic refilling for AC flattening. In the trabeculectomy group, four eyes had choroidal detachment, three eyes had AC flattening requiring an AC refilling and two eyes had hyphema.

It was concluded that, not only is the Ex-PRESS as effective as trabeculectomy in lowering IOP, it is also safer.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.